Intelligence · Patents
Patents expiring in 2040
Annual patent cliff calendar for 2040 — US pharmaceutical patents by expiration date.
- Patents
- 1,866
Quick answer
1,866 indexed pharmaceutical patents have expiration dates in 2040. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 10799559
NOPE for treatment of pathological muscle loss and weakness
granted -
US 10799549
Hepatoprotective traditional chinese medicine composition containing fructus ligustri lucidi, herba exliptae, radix paeoniae alba, rhizoma curcumae longae and clam extract, preparation method and use thereof
granted -
US 10799535
Engineered meganucleases with recognition sequences found in the human T cell receptor alpha constant region gene
granted -
US 10799561
Method for increasing cardiac inflow by administering a compound that binds RXFP1
granted -
US 10799514
Non-hormonal steroid modulators of NF-kappa beta for treatment of disease
granted -
US 10799511
Methods for reducing or ameliorating mortality and/or morbidity due to chlorine inhalation
granted -
US 10799512
Estrogen combination for treatment of multiple sclerosis
granted -
US 10799520
Lipotechoic acid for immune modulation
granted -
US 10799490
Pharmaceutical compositions of therapeutically active compounds
granted -
US 10799573
Pertussis vaccines and methods of making and using
granted -
US 10800781
Compounds useful as inhibitors of ATR kinase
granted -
US 10799472
Antiparasitic compositions and methods
granted -
US 10799466
Methods for delivering volatile anesthetics for regional anesthesia and/or pain relief
granted -
US 10799475
Substituted phenyl aziridine precursor analogs for inhibiting androgen-independent prostate cancer cell growth
granted -
US 10798955
Compositions of particulate coformulation
granted -
US 10799092
System and method for cleansing segments of a luminal network
granted -
US 10799567
Yeast-based immunotherapy and type I interferon sensitivity
granted -
US 10799525
Composition of novel carbohydrate drug for treatment of human diseases
granted -
US 10799485
Methods and compositions for treatment of epileptic disorders
granted -
US 10799468
Methods and compositions for treating conditions associated with an abnormal inflammatory responses
granted -
US 10799461
Methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells
granted -
US 10800813
Modulation of structured polypeptide specificity
granted -
US 10800833
Co-stimulatory domains for use in genetically-modified cells
granted -
US 10800854
Chimeric cytokine receptors and encoding nucleic acids
granted -
US 10800769
Heterocyclic inhibitors of ATR kinase
granted -
US 10799596
Pyrrolobenzodiazepine-antibody conjugates
granted -
US 10801076
Influenza A virus variants
granted -
US 10800855
Chimeric cytokine receptors and encoding nucleic acids
granted -
US 10808004
Triterpene-glycoside as sweetener or sweetener enhancer
granted -
US 10808246
Oligonucleotide-ligand conjugates and process for their preparation
granted -
US 10809323
Magnetic resonance maps for analyzing tissue
granted -
US 10806763
Compositions of polymeric myrcene
granted -
US 10808011
Recombinant HIV-1 envelope proteins and their use
granted -
US 10806742
Liquid phospholipid-containing compositions for the preparation of pharmaceuticals
granted -
US 10806740
Natural combination hormone replacement formulations and therapies
granted -
US 10806700
Oral dosage forms for delivery of therapeutic agents
granted -
US 10806697
Vaginal inserted estradiol pharmaceutical compositions and methods
granted -
US 10806716
Pharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity
granted -
US 10806750
RNAi therapy for hepatitis B virus infection
granted -
US 10806782
Hand, foot, and mouth vaccines and methods of manufacture and use thereof
granted -
US 10808010
Peptide inhibitors of phosphoglycerate mutase and methods of use
granted -
US 10808247
Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
granted -
US 10808230
Selection methods for genetically-modified T cells
granted -
US 10807987
Heterocyclic compound and use thereof
granted -
US 10808225
Use of PDL1 expressing cells to convert T cells into regulatory T cells
granted -
US 10806730
Methods of treating cancer with farnesyltransferase inhibitors
granted -
US 10806702
Bis-polymer lipid-peptide conjugates and nanoparticles thereof
granted -
US 10806781
Compositions and methods for live, attenuated alphavirus formulations
granted
Frequently asked questions
How many pharma patents expire in 2040?
1,866 published patents in our USPTO index have expiration dates falling in calendar year 2040.